Regenerative Medical Technology Group INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OID
Regenerative Medical Technologies Group announces a 67% increase in Q1 2025 sales compared to Q1 2024, along with achieving an operating profit of $134,000 for the quarter.
OID
8-K: Regenerative Medical Technology Group Achieves Operational Profitability and 52% Sales Growth in Q3
Regenerative Medical Technology Group (RMTG) reports achieving operational profitability and a 52% year-over-year sales increase in Q3, alongside a 75% gross profit margin.
OID
Meso Numismatics Inc. has completed its name and ticker symbol change to Regenerative Medical Technology Group Inc. (RMTG), effective October 21, 2024.
OID
Meso Numismatics Inc. is transitioning to Regenerative Medical Technology Group Inc. and reported positive operating cash flow for the quarter ended March 31, 2024.